MAP2K7 and acute myeloid leukemia: Sorafenib is commonly used as a treatment for AML patients with a FLT3-ITD mutation and functions as a tyrosine kinase inhibitor with high specificity for FLT3. At a molecular level, FLT3-ITD result in constitutive activation of receptors that lead to downstream activation of PI3K/AKT/mTOR, Ras/Raf/MEK/ERK, and JAK/STAT pathways.